Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 7 | 2023 | 106 | 2.320 |
Why?
|
| Tuberculosis | 8 | 2023 | 76 | 2.190 |
Why?
|
| Antitubercular Agents | 8 | 2023 | 33 | 2.050 |
Why?
|
| Aminopeptidases | 7 | 2023 | 9 | 1.870 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2022 | 112 | 1.690 |
Why?
|
| Health Status Disparities | 5 | 2023 | 705 | 1.560 |
Why?
|
| Premature Birth | 3 | 2023 | 94 | 1.560 |
Why?
|
| HIV Infections | 10 | 2022 | 2535 | 1.130 |
Why?
|
| Clioquinol | 2 | 2022 | 3 | 1.120 |
Why?
|
| Heart Arrest | 2 | 2022 | 52 | 0.900 |
Why?
|
| Mentors | 2 | 2022 | 143 | 0.860 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 6 | 0.850 |
Why?
|
| Pre-Eclampsia | 3 | 2020 | 68 | 0.780 |
Why?
|
| Ambroxol | 1 | 2022 | 3 | 0.760 |
Why?
|
| Bromhexine | 1 | 2022 | 4 | 0.760 |
Why?
|
| Hospital Mortality | 3 | 2020 | 206 | 0.750 |
Why?
|
| Antimalarials | 1 | 2022 | 63 | 0.740 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 55 | 0.730 |
Why?
|
| Malaria | 1 | 2022 | 90 | 0.720 |
Why?
|
| Pregnancy | 12 | 2023 | 1737 | 0.720 |
Why?
|
| Enzyme Inhibitors | 2 | 2020 | 457 | 0.570 |
Why?
|
| Humans | 28 | 2023 | 42163 | 0.480 |
Why?
|
| United States | 12 | 2023 | 5072 | 0.480 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 350 | 0.470 |
Why?
|
| Protease Inhibitors | 2 | 2012 | 53 | 0.450 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2022 | 230 | 0.440 |
Why?
|
| Stillbirth | 2 | 2023 | 20 | 0.400 |
Why?
|
| Drug Discovery | 2 | 2013 | 106 | 0.390 |
Why?
|
| Angiotensins | 2 | 2022 | 10 | 0.380 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 580 | 0.360 |
Why?
|
| Maternal Mortality | 2 | 2022 | 26 | 0.360 |
Why?
|
| Pregnancy Complications | 4 | 2023 | 134 | 0.360 |
Why?
|
| Retrospective Studies | 7 | 2023 | 2485 | 0.350 |
Why?
|
| Infant, Newborn | 3 | 2023 | 960 | 0.350 |
Why?
|
| Female | 17 | 2023 | 24018 | 0.340 |
Why?
|
| Databases, Factual | 3 | 2020 | 336 | 0.330 |
Why?
|
| Amidohydrolases | 1 | 2009 | 12 | 0.320 |
Why?
|
| Young Adult | 10 | 2023 | 4936 | 0.300 |
Why?
|
| Isoniazid | 2 | 2019 | 6 | 0.280 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3077 | 0.270 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 188 | 0.270 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 185 | 0.260 |
Why?
|
| Minority Groups | 2 | 2022 | 663 | 0.260 |
Why?
|
| Pregnancy Outcome | 2 | 2022 | 92 | 0.230 |
Why?
|
| Obesity | 2 | 2023 | 1131 | 0.230 |
Why?
|
| HIV | 2 | 2022 | 100 | 0.220 |
Why?
|
| Chromatography, Liquid | 3 | 2022 | 173 | 0.220 |
Why?
|
| Nickel | 1 | 2023 | 22 | 0.210 |
Why?
|
| Cobalt | 1 | 2023 | 26 | 0.210 |
Why?
|
| Program Evaluation | 2 | 2022 | 358 | 0.210 |
Why?
|
| Adult | 10 | 2023 | 13458 | 0.200 |
Why?
|
| Parturition | 1 | 2023 | 22 | 0.200 |
Why?
|
| Botswana | 1 | 2022 | 5 | 0.200 |
Why?
|
| Metals | 1 | 2023 | 113 | 0.200 |
Why?
|
| Chloroquine | 1 | 2022 | 19 | 0.200 |
Why?
|
| Adolescent | 8 | 2020 | 5950 | 0.190 |
Why?
|
| Middle Aged | 8 | 2020 | 11819 | 0.190 |
Why?
|
| Exopeptidases | 1 | 2022 | 2 | 0.190 |
Why?
|
| Microsomes, Liver | 1 | 2022 | 71 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2012 | 232 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1112 | 0.170 |
Why?
|
| Fetal Mortality | 1 | 2020 | 3 | 0.170 |
Why?
|
| Fetal Death | 1 | 2020 | 18 | 0.170 |
Why?
|
| Appendectomy | 1 | 2020 | 17 | 0.170 |
Why?
|
| Appendicitis | 1 | 2020 | 18 | 0.170 |
Why?
|
| Oxyquinoline | 1 | 2020 | 6 | 0.160 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2020 | 18 | 0.160 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 28 | 0.160 |
Why?
|
| Antiprotozoal Agents | 1 | 2020 | 33 | 0.160 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 53 | 0.160 |
Why?
|
| Risk Factors | 4 | 2023 | 3942 | 0.160 |
Why?
|
| Curriculum | 1 | 2022 | 311 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2020 | 47 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 93 | 0.150 |
Why?
|
| Chloroquinolinols | 1 | 2018 | 4 | 0.150 |
Why?
|
| Protein Binding | 1 | 2022 | 1076 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2017 | 28 | 0.140 |
Why?
|
| Comorbidity | 1 | 2020 | 725 | 0.140 |
Why?
|
| Length of Stay | 1 | 2017 | 231 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 72 | 0.120 |
Why?
|
| Logistic Models | 4 | 2020 | 1001 | 0.120 |
Why?
|
| Anti-HIV Agents | 2 | 2016 | 475 | 0.110 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 2803 | 0.100 |
Why?
|
| Rats | 4 | 2022 | 3701 | 0.100 |
Why?
|
| Amidines | 1 | 2012 | 3 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2019 | 587 | 0.100 |
Why?
|
| Career Choice | 2 | 2022 | 51 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2021 | 1737 | 0.080 |
Why?
|
| Child | 3 | 2022 | 3381 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 88 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2010 | 273 | 0.080 |
Why?
|
| Animals | 6 | 2022 | 16695 | 0.070 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2010 | 168 | 0.070 |
Why?
|
| Universities | 2 | 2022 | 539 | 0.070 |
Why?
|
| HIV-1 | 1 | 2013 | 747 | 0.070 |
Why?
|
| Aged | 1 | 2020 | 7982 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1188 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1559 | 0.060 |
Why?
|
| Students | 2 | 2022 | 617 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 1058 | 0.060 |
Why?
|
| Male | 6 | 2022 | 22779 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2019 | 845 | 0.060 |
Why?
|
| Prevalence | 2 | 2018 | 1597 | 0.050 |
Why?
|
| Microsomes | 1 | 2022 | 55 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2022 | 21 | 0.050 |
Why?
|
| Glucuronides | 1 | 2022 | 23 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 512 | 0.050 |
Why?
|
| Leadership | 1 | 2022 | 84 | 0.040 |
Why?
|
| Capacity Building | 1 | 2022 | 99 | 0.040 |
Why?
|
| Obstetric Labor, Premature | 1 | 2020 | 9 | 0.040 |
Why?
|
| Methionine | 1 | 2020 | 27 | 0.040 |
Why?
|
| Chemistry, Physical | 1 | 2020 | 50 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 64 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 230 | 0.040 |
Why?
|
| Sepsis | 1 | 2020 | 90 | 0.040 |
Why?
|
| Biotransformation | 1 | 2019 | 68 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 226 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 916 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 458 | 0.040 |
Why?
|
| Mice | 2 | 2020 | 6490 | 0.040 |
Why?
|
| Abortion, Induced | 1 | 2020 | 90 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 181 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 686 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 560 | 0.040 |
Why?
|
| Drug Stability | 1 | 2018 | 127 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 326 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 311 | 0.030 |
Why?
|
| Kidney | 1 | 2020 | 363 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 192 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 289 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 249 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1266 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 115 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 245 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 638 | 0.030 |
Why?
|
| Health Surveys | 1 | 2018 | 401 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 708 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 850 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 482 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 585 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1221 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 122 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 151 | 0.030 |
Why?
|
| Depression | 1 | 2020 | 837 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 137 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 246 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 491 | 0.020 |
Why?
|